Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Effect of 12 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg and 5/5 µg) Delivered by the Respimat® Inhaler, on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD)[Torracto (TM)]
Brief Summary: The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg; 5/5 µg) with placebo on exercise tolerance after 12 weeks of treatment in patients with COPD.


Options:
A: Arm Label: Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol | Arm Label: Vilanterol 25 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol; Assigned to Arm(s): Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol 25 Inhalation Powder
B: Arm Label: Olodaterol (BI 1744) Low; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Olodaterol (BI 1744) High; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Formoterol 12mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) Low | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) High | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Formoterol 12mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: NVA237 100 µg; Type: EXPERIMENTAL; Interventions: Drug: NVA237 100 µg | Arm Label: NVA237 200 µg; Type: EXPERIMENTAL; Interventions: Drug: NVA237 200 µg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NVA237 100 µg; Assigned to Arm(s): NVA237 100 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: NVA237 200 µg; Assigned to Arm(s): NVA237 200 µg
D: Arm Label: tiotropium+olodaterol low dose; Type: EXPERIMENTAL; Interventions: Device: Respimat inhaler, Drug: tiotropium+olodaterol (low dose) | Arm Label: tiotropium+olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium + olodaterol (high dose), Device: Respimat inhaler | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Respimat inhaler, Drug: placebo to tiotropium+olodaterol | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): tiotropium+olodaterol low dose | Intervention Type: DRUG; Name: tiotropium+olodaterol (low dose); Assigned to Arm(s): tiotropium+olodaterol low dose | Intervention Type: DRUG; Name: tiotropium + olodaterol (high dose); Assigned to Arm(s): tiotropium+olodaterol high dose | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): tiotropium+olodaterol high dose | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: placebo to tiotropium+olodaterol; Assigned to Arm(s): placebo

Answer: D